EASTERN COOPERATIVE ONCOLOGY GROUP - WISCONSIN STUDIES

东部肿瘤合作组 - 威斯康星州研究

基本信息

  • 批准号:
    7661563
  • 负责人:
  • 金额:
    $ 62.1万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1978
  • 资助国家:
    美国
  • 起止时间:
    1978-06-01 至 2010-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): This application seeks support for the activities of the Eastern Cooperative Oncology Group (ECOG) at the University of Wisconsin Comprehensive Cancer Center (UWCCC) and affiliated institutions. The clinical programs of the UWCCC are designed to improve both the treatment and care of cancer patients as well as to reduce the burden of the cancer problem in general. Our long association with the Eastern Cooperative Oncology Group (ECOG) has been beneficial in enhancing these goals. UWCCC Investigators have a history of strong commitment to ECOG accrual as well as administrative and scientific leadership. UWCCC clinics are organized along disease specific lines with efforts to enhance the multidisciplinary approaches needed for today's optimal cancer care and clinical research. During the last grant cycle this approach has been strengthened with recruitment in Medical Oncology and Surgery, new clinic space and enhancement of computerized research database facilities. All of this has improved our ECOG effort as manifested by consistent high accrual and group leadership activities. UW investigators chair the GU and Thoracic committees and co-chair the Pharmacology committee. UW investigators will lead chemoprevention efforts in ECOG. Institutional evaluations consistently rank the UW ECOG program at or near the top in categories of accrual, administrative and scientific leadership. UW ECOG affiliates continue to contribute with significant accrual and high quality data management and rank among the best in ECOG. ECOG studies and a clinical trials approach in cancer care are essential for continued high quality in the cancer programs at UW and throughout the region. ECOG studies serve as a core curriculum for trainees in Hematology and Medical and Radiation Oncology and as a basis for clinical strategies. The ECOG program remains an important component of the UWCCC cancer research effort and UWCCC contributions to ECOG remain equally important to the Group.
描述(由申请人提供):本申请寻求对威斯康星大学综合癌症中心(UWCCC)的东部合作肿瘤学小组(ECOG)及其附属机构的活动的支持。UWCCC的临床计划旨在改善癌症患者的治疗和护理,并总体上减轻癌症问题的负担。我们与东部合作肿瘤学小组(ECOG)的长期合作对促进这些目标是有益的。 UWCCC的调查人员历来坚定地致力于经社理事会的收益以及行政和科学领导。UWCCC诊所是按照疾病特定的路线组织的,努力加强当今最佳癌症护理和临床研究所需的多学科方法。在上一个赠款周期中,通过在内科肿瘤学和外科招聘、新的诊所空间和加强计算机化的研究数据库设施,加强了这一方法。所有这些都改善了我们经社理事会的努力,这体现在持续的高应收性和小组领导活动上。威斯康星大学的调查员担任GU和Thoracic委员会的主席,并担任药理学委员会的联合主席。威斯康星州大学的调查人员将领导ECOG的化学预防工作。 机构评估始终将威斯康星州大学ECOG项目在应计、行政和科学领导能力类别中排名靠前或接近靠前。威斯康星大学经济和社会理事会的分支机构继续以显著的应计和高质量的数据管理作出贡献,并在经济和社会理事会中名列前茅。在癌症护理方面的ECOG研究和临床试验方法对于华盛顿大学和整个地区癌症项目的持续高质量至关重要。ECOG研究是血液学、内科和放射肿瘤学受训人员的核心课程,也是临床战略的基础。ECOG计划仍然是UWCCC癌症研究工作的重要组成部分,UWCCC对ECOG的贡献对该小组仍然同样重要。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Brad Kahl其他文献

Brad Kahl的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Brad Kahl', 18)}}的其他基金

Phase I Study of Rituximab with L2-7001 (Aldesleukin) for Non-Hodgkin's Lymphoma
利妥昔单抗联合 L2-7001(Aldesleukin)治疗非霍奇金淋巴瘤的 I 期研究
  • 批准号:
    7043907
  • 财政年份:
    2003
  • 资助金额:
    $ 62.1万
  • 项目类别:
EASTERN COOPERATIVE ONCOLOGY GROUP - WISCONSIN STUDIES
东部肿瘤合作组 - 威斯康星州研究
  • 批准号:
    8284229
  • 财政年份:
    1978
  • 资助金额:
    $ 62.1万
  • 项目类别:
EASTERN COOPERATIVE ONCOLOGY GROUP - WISCONSIN STUDIES
东部肿瘤合作组 - 威斯康星州研究
  • 批准号:
    8465828
  • 财政年份:
    1978
  • 资助金额:
    $ 62.1万
  • 项目类别:
EASTERN COOPERATIVE ONCOLOGY GROUP - WISCONSIN STUDIES
东部肿瘤合作组 - 威斯康星州研究
  • 批准号:
    7426841
  • 财政年份:
    1978
  • 资助金额:
    $ 62.1万
  • 项目类别:
EASTERN COOPERATIVE ONCOLOGY GROUP - WISCONSIN STUDIES
东部肿瘤合作组 - 威斯康星州研究
  • 批准号:
    8079081
  • 财政年份:
    1978
  • 资助金额:
    $ 62.1万
  • 项目类别:
EASTERN COOPERATIVE ONCOLOGY GROUP - WISCONSIN STUDIES
东部肿瘤合作组 - 威斯康星州研究
  • 批准号:
    7869601
  • 财政年份:
    1978
  • 资助金额:
    $ 62.1万
  • 项目类别:

相似海外基金

Research Project 2 Proteogenomic-guided therapeutic targeting of breast cancer patient-derived xenograft metastases
研究项目 2 蛋白质基因组引导的乳腺癌患者异种移植转移的治疗靶向
  • 批准号:
    10733315
  • 财政年份:
    2023
  • 资助金额:
    $ 62.1万
  • 项目类别:
SQLE and Sterols Contribute to Racial Disparity in ER+ Breast Cancer Patient Survival
SQLE 和甾醇导致 ER 乳腺癌患者生存率的种族差异
  • 批准号:
    10571020
  • 财政年份:
    2023
  • 资助金额:
    $ 62.1万
  • 项目类别:
Establishing industrial production of components that enable expanding accessibility of PET imaging to cancer patient population.
建立组件的工业化生产,使癌症患者群体能够更容易地获得 PET 成像。
  • 批准号:
    10698218
  • 财政年份:
    2023
  • 资助金额:
    $ 62.1万
  • 项目类别:
Washington University PDX Development and Trial Center - Evaluation of Abemaciclib in Combination with Olaparib in Ovarian Cancer and Breast Cancer Patient-derived Xenograft Models
华盛顿大学 PDX 开发和试验中心 - Abemaciclib 联合 Olaparib 在卵巢癌和乳腺癌患者异种移植模型中的评估
  • 批准号:
    10582164
  • 财政年份:
    2022
  • 资助金额:
    $ 62.1万
  • 项目类别:
Towards Cancer Patient Empowerment for Optimal Use of Antithrombotic Therapy at the End of Life
增强癌症患者在临终时最佳使用抗血栓治疗的能力
  • 批准号:
    10039823
  • 财政年份:
    2022
  • 资助金额:
    $ 62.1万
  • 项目类别:
    EU-Funded
Convening a gynecologic cancer patient advisory group to adapt a digital health tool
召集妇科癌症患者咨询小组以采用数字健康工具
  • 批准号:
    460767
  • 财政年份:
    2022
  • 资助金额:
    $ 62.1万
  • 项目类别:
    Miscellaneous Programs
Towards Cancer Patient Empowerment for Optimal Use of Antithrombotic Therapy at the End of Life
增强癌症患者在临终时最佳使用抗血栓治疗的能力
  • 批准号:
    10038000
  • 财政年份:
    2022
  • 资助金额:
    $ 62.1万
  • 项目类别:
    EU-Funded
Longitudinal mixed method investigation of social networks and affective states as determinants of smoking behavior among cancer patient
社会网络和情感状态作为癌症患者吸烟行为决定因素的纵向混合方法调查
  • 批准号:
    10513670
  • 财政年份:
    2021
  • 资助金额:
    $ 62.1万
  • 项目类别:
Improving the translational value of head and neck cancer patient-in-mouse models
提高头颈癌小鼠模型的转化价值
  • 批准号:
    10598311
  • 财政年份:
    2021
  • 资助金额:
    $ 62.1万
  • 项目类别:
Improving the translational value of head and neck cancer patient-in-mouse models
提高头颈癌小鼠模型的转化价值
  • 批准号:
    10442585
  • 财政年份:
    2021
  • 资助金额:
    $ 62.1万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了